This year’s Summer Enrichment Program for college undergraduates welcomed 20 high-performing students who learned what it takes to gain entry to medical school.
John Harris MD, PhD, has dedicated his research to better understanding what causes vitiligo, an autoimmune disease that results in the appearance of white spots on the skin, according to an article in the Worcester Telegram & Gazette.
Ann Marshak-Rothstein, PhD, will use the Lupus Insight Prize award to explore the regulatory role of toll-like receptors in an animal model of cutaneous lupus that has strong similarities to the human disease.
Shan Lu, MD, PhD, has received $17.3 million from the National Institute of Allergy and Infectious Diseases to develop and produce an optimized HIV vaccine to be used in Phase II human clinical trials.
UMMS scientists have performed the first CRISPR/Cas9 screen to discover human proteins that Zika virus needs for replication. This work, led by Abraham Brass, MD, PhD, reveals new leads that may be useful for halting Zika, dengue and other emerging viral infections.
UMass Medical School faculty discussed how to deal with Worcester’s opioid epidemic at a City Hall forum on Monday, June 20, highlighting the need for more federal funding.
In this Women In Science video, MD/PhD student Miriam Madsen talks about her PhD project to develop technologies that improve quality of life and bolster independence for people with temporary or chronic physical and neurodevelopmental disabilities.
Cancer survivor Liam Fitzgerald, 10, otherwise known as the “Fist-bump Kid,” stole the show at the June 16 breakfast to kick off the campaign for the 18th annual UMass Medicine Cancer Walk/Run. The event is Sept. 25.
School of Medicine student Nitin Shrivastava belongs to an international consortium of researchers and clinicians working in Guatemala to test and disseminate use of a free smartphone app that detects leukocoria and increases early diagnosis of retinoblastoma.
A UMMS study suggests some patients with hepatitis C face barriers to receiving the newest medications to treat the virus. The paper examined the use of sofosbuvir and simeprevir, medications that have been very effective treating HCV, among members of MassHealth.